Anne Bang, Ph.D.

anne bang

Anne Bang, Ph.D.

Director, Cell Biology

Anne Bang's Research Focus

Phenomena or Processes > Cell Biology, Embryonic/Pluripotent Stem Cells, Neurogenesis, Neurodegeneration, Development and Differentiation, Development of Neuronal Circuits, Neurogenesis, Synaptic Transmission, Synapse Function, Synapse Formation and Maturation, Neuron-Glia Interactions in Myelin, Neurobiology, Neurodegeneration, Neurotransmitters
Techniques and Technology > Molecular Genetics, High Content Imaging, Fluorescence Microscopy, Electrophysiology, Cellular and Molecular Imaging, Drug Discovery, In vivo Modeling, Microarrays
Related Diseases > Neurodegenerative and Neuromuscular Diseases, Alzheimer's Disease, Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease), Congenital Disorders of Glycosylation, Glycosylation-Related Disorders, Multiple Sclerosis, Muscular Dystrophy, Aging-Related Diseases
Research Models > Human Embryonic Stem Cells, Human Cell Lines, Human Adult/Somatic Stem Cells

Dr. Anne Bang is an experienced cell biologist and stem cell expert who leads efforts at the Prebys Center to develop patient cell specific and human induced pluripotent stem cell (hiPSC)-based disease models for drug screening and target identification. Her research program is primarily focused on neurological and neuromuscular disease, with the aim of designing human cell based models and assays that reflect higher order cellular functions and recapitulate disease phenotypes, yet have the throughput and reproducibility required for drug discovery. Towards this goal her group has worked to develop a suite of foundational high throughput assays to monitor neuronal morphology, mitochondrial function, and electrophysiology, using high content screening, and multi-electrode array formats. They have conducted high-throughput drug screens on muscular dystrophy patient cells, hiPSC-derived cardiomyocytes, and hiPSC-derived neurons, including from Alzheimer’s patient specific hiPSC. Anne is a principal investigator for the National Institute of Mental Health (NIMH) National Cooperative Reprogrammed Cell Research Groups consortium “iPSC-based platform development for major psychiatric disorder modeling and discovery", and also receives research support from rare disease foundations and pharma sponsored collaborations.

Anne Bang's Bio

Dr. Bang has over 20 years of experience in the fields of developmental and stem cell biology. She obtained a B.S. degree from Stanford University, a Ph.D. in Biological Sciences from the University of California, San Diego, and did postdoctoral training in the Neurobiology Laboratory at the Salk Institute for Biological Sciences. Thematically, her thesis and postdoctoral studies focused on molecular mechanisms that regulate neurogenesis and patterning in the developing nervous system. Anne’s experience in stem cell biology began in 2005 when she joined ViaCyte, Inc. where she served as Director of Stem Cell Research and managed an interdisciplinary group working to develop human embryonic stem cells (hESC) as a replenishable source of pancreatic cells for the treatment of diabetes. Her efforts focused on optimization of the differentiation process, and then on advancing the cell therapy product into development, scaled manufacturing, product characterization, and safety assessment. Anne is a co-inventor on multiple ViaCyte patents, and her team’s contributions played a key role in securing a $20 MM California Institute of Regenerative Medicine (CIRM) Award.  In June of 2010, SBP recruited Anne as Director of Cell Biology to lead efforts in stem cell-based disease modeling at the Conrad Prebys Center for Chemical Genomics. Her role includes leading internal research projects, as well as external collaborations with academic and industry partners. She is an internship mentor for the CIRM Bridges to Stem Cell Research Program, and serves on advisory boards for multiple biotechnology companies.

general accessory


Hung SS, Chrysostomou V, Li F, Lim JK, Wang JH, Powell JE, Tu L, Daniszewski M, Lo C, Wong RC, Crowston JG, Pébay A, King AE, Bui BV, Liu GS, Hewitt AW
Invest Ophthalmol Vis Sci 2016 Jun 1;57(7):3470-6
D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, Moorman MA, Kroon E, Carpenter MK, Baetge EE
Nat Biotechnol 2006 Nov;24(11):1392-401
Bang AG, Carpenter MK
Science 2008 Apr 4;320(5872):58-9
Bardy C, van den Hurk M, Eames T, Marchand C, Hernandez RV, Kellogg M, Gorris M, Galet B, Palomares V, Brown J, Bang AG, Mertens J, Böhnke L, Boyer L, Simon S, Gage FH
Proc Natl Acad Sci U S A 2015 May 19;112(20):E2725-34
Schulz TC, Young HY, Agulnick AD, Babin MJ, Baetge EE, Bang AG, Bhoumik A, Cepa I, Cesario RM, Haakmeester C, Kadoya K, Kelly JR, Kerr J, Martinson LA, McLean AB, Moorman MA, Payne JK, Richardson M, Ross KG, Sherrer ES, Song X, Wilson AZ, Brandon EP, Green CE, Kroon EJ, Kelly OG, D'Amour KA, Robins AJ
PLoS One 2012;7(5):e37004
Kelly OG, Chan MY, Martinson LA, Kadoya K, Ostertag TM, Ross KG, Richardson M, Carpenter MK, D'Amour KA, Kroon E, Moorman M, Baetge EE, Bang AG
Nat Biotechnol 2011 Jul 31;29(8):750-6